Navigation Links
MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference
Date:11/25/2008

VALENCIA, Calif., Nov. 25 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Piper Jaffray 20th Annual Health Care Conference on Tuesday, December 2, 2008 at 2:30 PM (EST) at the New York Palace Hotel in New York City.

Interested parties can access a link to the live web cast of the presentation in the Investor Relations section of the Company's website at http://www.mannkindcorp.com. A replay of the presentation will be available for 14 days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA, which has completed Phase 3 clinical trials, and MKC253, which is currently in phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes. MannKind maintains a website at https://www.mannkindcorp.com to which MannKind regularly posts copies of its press release as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to email alerts that are sent automatically when MannKind issues press releases, files its reports with the SEC or posts certain other information to the website.


'/>"/>
SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. MannKind to Present at the Rodman & Renshaw Annual Global Investment Conference
2. MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008
3. MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility
4. MannKind to Present at the UBS Global Life Sciences Conference
5. MannKind Corporation Reports Second Quarter Financial Results
6. MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
7. MannKind to Present at Upcoming Conferences
8. MannKind Corporation Reports First Quarter Financial Results
9. MannKind to Present at the Morgan Stanley Healthcare Conference
10. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
11. Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Bio-Techne Corporation (NASDAQ: TECH ) announced today ... serve in a newly created position of Senior Vice ... be responsible for managing the operations of Bio-Techne,s Protein ... in July 2014 and the recently acquired CyVek business. ... ProteinSimple develops and commercializes proprietary systems and consumables that ...
(Date:11/24/2014)...  IGI Laboratories, Inc. (NYSE MKT: IG), a ... company, today announced it has submitted an additional abbreviated ... Drug Administration (FDA), which brings the Company,s total number ... submissions now pending at the FDA. ... Company, commented, "Our team here at IGI has continued ...
(Date:11/24/2014)... 24, 2014 VolitionRx Limited (OTCQB: VNRX), ... cancer and other conditions, today announced that data from its ... for Business BioWin Day 2014, being held November 26, 2014 ... from VolitionRx,s lung cancer pilot study, the samples for which ... Universitaire (CHU) de Liege in Belgium . ...
(Date:11/24/2014)... November 23, 2014 One of the most ... optics and photonics is now available to high school and ... cost. SPIE, the international society for optics and photonics ... complete SPIE Digital Library available to high schools ... “Light-based technologies are integral to all areas of life in ...
Breaking Biology Technology:Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3IGI Laboratories, Inc. Announces ANDA Submission 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6SPIE Digital Library Now Available to High Schools, Two-Year Colleges at No or Low Cost 2
... Business and technology opportunities are affording today,s ... decades ago—the chance to create successful new companies ... leaders who will speak at Keck Graduate Institute ... of KGI,s Focus Track Fridays seminar series, executives ...
... Pharmasset, Inc. (Nasdaq: VRUS ), a ... commercializing novel drugs to treat viral infections, today reported ... ended September 30, 2011. At fiscal year end Pharmasset ... used $21.7 million of our cash and cash equivalents ...
... inVentiv Health, Inc., offering best-in-class clinical, commercial ... today that it has been selected by the ... operations support, as well as recruiting and sales ... for Type 2 diabetes. inVentiv ...
Cached Biology Technology:'Garage' Start-ups Now Possible in Life Sciences Industry 2Pharmasset Reports Fiscal Year End 2011 Financial Results 2Pharmasset Reports Fiscal Year End 2011 Financial Results 3Pharmasset Reports Fiscal Year End 2011 Financial Results 4Pharmasset Reports Fiscal Year End 2011 Financial Results 5Pharmasset Reports Fiscal Year End 2011 Financial Results 6Pharmasset Reports Fiscal Year End 2011 Financial Results 7Pharmasset Reports Fiscal Year End 2011 Financial Results 8inVentiv Health Selected to Provide Sales Operations Support for Santarus 2inVentiv Health Selected to Provide Sales Operations Support for Santarus 3inVentiv Health Selected to Provide Sales Operations Support for Santarus 4
(Date:11/5/2014)... professor of biology in the UTSA College of ... nation selected to receive a two-year $300,00 National ... Research (EAGER). The funding supports President Obama,s BRAIN ... create new technology that will demystify complex brain ... in neuroscience are broken into the interactions of ...
(Date:11/4/2014)... right amount of death at the right time might ... new research that could help in understanding animal populations, ... In a paper in the journal Trends in ... European colleagues conclude that the kind of positive population ... individuals, or mortality, depends on the size and developmental ...
(Date:11/4/2014)... England , November 4, 2014 ... and vertical market growth   Fuel3D , ... has closed a funding round totaling $6.4 million (£4 million). ... million) funding secured earlier this year and paves the way ... in 2015. The funding round was led by ...
Breaking Biology News(10 mins):UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3When less is more: Death in moderation boosts population density in nature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3
... such as Alzheimer,s disease, Parkinson,s disease, and amyotrophic ... for patients, put a tremendous burden on family ... The most consistent risk factor for developing ... increase in life expectancy, the incidence of individuals ...
... 2008 On the day Americans elect a new president, ... at the University of Houston and outline the daunting global ... Trenberth, head of climate analysis at the National Center for ... manmade global warming at a colloquium Tuesday, Nov. 4. ...
... Although research has linked inbreeding with elevated rates of ... study finds it plays no part in the high ... recently examined 2,000 adult and juvenile salamanders and found ... missing, extra or dwarfed digits (equivalent to fingers and ...
Cached Biology News:3-substituted indolones as novel therapeutic compounds for neurodegenerative conditions 2Climate change expert to discuss grim global warming predictions 2Study rules out inbreeding as cause of amphibian deformities 2
... state-of-the-art separation system using the asymmetric flow ... integrates easily with Wyatts multi-angle light scattering ... as the Optilab DSP. The combined system ... of the particles/molecules separated by the AFFF ...
Monoclonal antibodies conjugated with rhodamine...
... Both compact and lightweight, the Moticam ... microscope through the eyepiece, eyetube, or trinocular ... easy to use Plug-and-Play Images 2.0ML software ... Image manipulation tools to maximize resolution for ...
5X StabilCoat Immunoassay Stabilizer is a 5X concentrate solution of StabilCoat Immunoassay Stabilizer. The shelf-life of 5X StabilCoat Immunoassay Stabilizer is 2 years when stored at 4C. Product ...
Biology Products: